Management of Gastric Outlet Obstruction
For patients with malignant gastric outlet obstruction who have good functional status and life expectancy >2 months, surgical gastrojejunostomy (preferably laparoscopic) should be the primary consideration, while endoscopic ultrasound-guided gastroenterostomy (EUS-GE) represents an excellent alternative with potentially superior outcomes, and enteral stenting should be reserved for patients who are not candidates for these more durable interventions 1.
Decision Algorithm
The management approach depends on three critical factors that must be assessed upfront:
1. Patient Selection Based on Prognosis and Functional Status
Life expectancy >2 months AND surgically fit with good functional status: Surgical gastrojejunostomy is recommended 1
- Use laparoscopic approach over open (lower blood loss, shorter hospital stay) 1
Not surgical candidates OR limited life expectancy: Consider EUS-GE or enteral stenting 1, 2
2. Anatomic Considerations
Critical contraindications to stenting:
- Multiple luminal obstructions
- Severely impaired gastric motility
- In these scenarios, place a venting gastrostomy instead 1
3. Institutional Expertise
EUS-GE is emerging as the optimal intervention based on the most recent high-quality evidence 3. A 2026 network meta-analysis of 6,110 patients demonstrated:
- Lower reintervention rates compared to enteral stenting (OR: 0.29,95% CI: 0.17-0.51)
- Higher clinical success than stenting (OR: 2.46,95% CI: 1.50-4.04)
- Fewer adverse events than both surgical gastrojejunostomy (OR: 0.33) and stenting (OR: 0.61)
However, EUS-GE requires advanced endoscopic expertise and currently lacks FDA-approved dedicated devices 1.
Comparative Outcomes
Surgical Gastrojejunostomy
- Advantages: Durable, bypasses obstruction away from tumor
- Disadvantages: More invasive, longer recovery
- Best for: Surgically fit patients with reasonable life expectancy
EUS-Guided Gastroenterostomy
- Advantages: Mimics surgical bypass, lower reintervention rates than stenting, fewer complications than surgery 3, 4
- Disadvantages: Requires specialized expertise, no FDA-approved devices
- Best for: Patients at centers with advanced endoscopy capability
Enteral Stenting
- Advantages: Minimally invasive, rapid symptom relief
- Disadvantages: Higher reintervention rates (recurrent obstruction, stent migration, tumor ingrowth)
- Best for: Poor surgical candidates, very limited life expectancy (<2 months), or when EUS-GE unavailable 1, 2
Critical Pitfalls to Avoid
Do not use enteral stents in patients with:
- Multiple points of obstruction
- Severely impaired gastric motility
- These patients need venting gastrostomy 1
Multidisciplinary decision-making is mandatory: All decisions should involve oncologists, surgeons, and endoscopists, considering the obstruction characteristics, patient expectations, prognosis, and planned therapies 1
Avoid prolonged nasogastric tube use: NG tubes are appropriate for acute decompression when endoscopy is not immediately feasible, but should not be used long-term 5
Emerging Evidence
Recent 2025-2026 literature increasingly supports EUS-GE as first-line therapy when expertise is available 3, 5, 4. The technique offers a middle ground between the invasiveness of surgery and the durability limitations of stenting. In centers lacking EUS-GE expertise, surgical gastrojejunostomy remains the gold standard for appropriate candidates 3.
Supportive Care
Regardless of intervention chosen: